Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2012

View Archived Issues

Eisai describes new clinical candidate for anxiety and depression

Novel nanotechnology targets t-PA to obstructed blood vessels

Novel DAAO inhibitor shows potential to treat schizophrenia

Small molecule shows potential for as a contraceptive for men

New DNA tests developed for hereditary diseases

Medivir moves MIV-711 into phase Ib testing

Orexo plans NDA for sublingual buprenorphine/naloxone product

Pluristem and BCRT renew 5-year collaboration

New phase III data disclosed on Inavir

Novel prosthetic incorporates retinal code to restore vision

NIH awards HIV vaccine research grants

Aurum Biosciences and Oxygen Biotherapeutics present novel Oxycyte data

Scientists at Novartis synthesize novel CDK9 inhibitors

Investigation at Sphaera Pharma yields new PI3K/mTOR inhibitors

Boehringer Ingelheim Pharma reports new SYK inhibitors

New pim-1/2 inhibitors developed

Novel tyrosine kinase inhibitors patented by Pierre Fabre Medicament

Glymera enters phase IIb trial for uncontrolled type 2 diabetes

FDA extends tofacitinib NDA PDUFA date

FDA to discuss Gattex NDA at advisory committee meeting

Vernalis kicks off receptor occupancy study of V-81444

Foundation Fighting Blindness to fund eight projects for retinal degenerative diseases

NICE issues new guidance on bevacizumab

VolitionRX and Belgian hospital sign agreement for prospective colon cancer trial

Research collaboration begins for delivery of microRNA-based therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...